



NDA 21479/S-005

SUPPLEMENT APPROVAL

Valeant Pharmaceuticals North America, LLC
Attention: Isabelle Lefebvre, MSc. RA, RAC EU & US
Director, Branded Rx & Gx Products Portfolio
US Regulatory Affairs
400 Somerset Corporate Boulevard
Bridgewater, NJ, 08807

Dear Ms. Lefebvre:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 29, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Zelapar (selegiline hydrochloride) orally disintegrating tablets, 1.25 mg.

We acknowledge receipt of your amendments dated February 10, 2010, and February 23, 2012.

This "Prior Approval" supplemental new drug application includes the following:

- Proposal for the addition of Phase IV animal study results into the "Use in Specific Populations" and "Nonclinical Toxicology" sections of the Prescribing Information
- Proposal for the addition of Phase IV pharmacokinetic studies related to hepatic and renal impairment and *in vitro* drug interaction studies into the "Clinical Pharmacology" section of the Prescribing Information
- Provision for compliance with the Federal Register final rule issued January 24, 2006, "Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products" [21 CFR 201.56 and 201.57], commonly referred to as the physician labeling rule (PLR).

In addition, we note that drugs that have an effect on central dopaminergic activity may lead to certain side effects, which warrant a detailed description in the Prescribing Information. Therefore, to be consistent and thorough, class language has been added to the "Warnings and Precautions" section of the Zelapar labeling, which includes the following:

- Falling Asleep During Activities of Daily Living and Somnolence
- Impulse Control/Compulsive Behaviors

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tracy Peters, Regulatory Project Manager, at (301) 796-2953.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
07/31/2014